Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: A multivariate analysis

Archives of Surgery

Volumn 142, Issue 3, 2007, Pages 289-293

  Machens, Andreas ^a   Ukkat, Jörg ^a   Hauptmann, Steffen ^a   Dralle, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SURGICAL TECHNIQUE; THYROID MEDULLARY CARCINOMA;

CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 33947371271     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.142.3.289     Document Type: Article

References (24)

1. Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF; GTE Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077-6084.
2. Osamura RY, Yasuda O, Kawakami T, Itoh Y, Inada K, Kakudo K. Immunoelectron microscopic demonstration of regulated pathway for calcitonin and constitutive pathway for carcinoembryonic antigen in the same cells of human medullary carcinomas of thyroid glands. Mod Pathol. 1997;10:7-11.
3. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53:278-285.
4. Behr TM, Gratz S, Markus PM, et al. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma. Cancer. 1997;80:2436-2457.
5. Juweid M, Sharkey RM, Swayne LC, Goldenberg DM. Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies. Surgery. 1997;122:1156-1165.
6. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med. 1998;39:1172-1178.
7. Wells SA, Haagensen DE, Linehan WM, Farrell RE, Dilley WG. The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinoma. Cancer. 1978;42:1498-1503.
8. Rougier P, Calmettes C, Laplanche A, et al. The values of calcitonin and carcinoembryonic antigen in the treatment and management of nonfamilial medullary thyroid carcinoma. Cancer. 1983;51:855-862.
9. Tisell LE, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 1986;99:60-66.
10. Dralle H, Damm I, Scheumann GF, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today. 1994;24:112-121.
11. Röher HD, Simon D, Goretzki PE. Guidelines in oncologic surgery: malignant thyroid tumors. Langenbecks Arch Chir Suppl Kongressbd. 1997;114(suppl 2):142-145.
12. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26:22-28.
13. Hinze R, Holzhausen HJ, Gimm O, Dralle H, Rath FW. Primary hereditary medullary thyroid carcinoma: C-cell morphology and correlation with preoperative calcitonin levels. Virchows Arch. 1998;433:203-208.
14. World Health Organization. International Histological Classification of Tumours. 2nd ed. Berlin, Germany: Springer-Verlag; 1988.
15. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999;229:880-888.
16. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029-2034.
17. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, Mass: Little Brown & Co Inc; 1987.
18. 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47:247-255.
19. Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U, Dralle H. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer. 2000;88:1909-1915.
20. Weber T, Schilling T, Frank-Raue K, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery. 2001;130:1044-1049.
21. Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88:2070-2075.
22. Machens A, Holzhausen HJ, Dralle H. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Surgery. 2006;139:28-32.
23. Machens A, Hinze R, Lautenschläger C, Thomusch O, Dralle H. Thyroid carcinoma invading the cervicovisceral axis: routes of invasion and clinical implications. Surgery. 2001;129:23-28.
24. Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg. 1999;230:697-707.